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Abstract
Background: Sub-Saharan Africa is the world’s worst HIV-AIDS affected region. More interventions to manage this
pandemic are urgently required. Transmission of the virus through an exchange of saliva is rarely known to occur.
This project sought to verify statistically previous findings in our laboratory, that crude saliva from uninfected
individuals together with its purified mucin components inhibited HIV-1, whilst mucins from infected saliva did not
show this inhibition, in an in vitro assay.
Methods: Saliva was extracted in 4 M guanidinium hydrochloride and proteolytic inhibitors at pH 6.5, followed by
the isolation of MUC5B and MUC7 by Sepharose 4B gel filtration and further purification of these mucins by
density-gradient ultra-centrifugation in caesium chloride. Agarose gel electrophoresis, Western blotting and amino
acid compositional analysis determined the size, purity and identity of the mucins. The inhibitory activity of crude
saliva and purified MUC5B and MUC7, from HIV negative (n=20) and HIV positive (n=20) donors, was tested by their
incubation with subtype C HIV-1 and subsequent infection of peripheral blood mononuclear cells (PBMCs). PCR was
done on tandem repeat regions of MUC5B and MUC7 DNA to investigate whether any association existed between
gene polymorphism and susceptibility to infection.
Results: There was an inter-individual variation in the amounts of MUC5B and MUC7 in saliva. In contrast to
previous studies, crude saliva and purified mucins from both HIV negative and HIV positive individuals inhibited the
infection of HIV-1 in an in vitro assay. DNA analysis of the tandem repeat regions of MUC5B and MUC7 revealed no
difference between groups.
Conclusions: Crude saliva and its mucins, MUC5B and MUC7, from both uninfected controls and HIV positive
individuals inhibited HIV-1 in an in vitro assay.
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Background
Human Immunodeficiency Virus – Acquired Immune
Deficiency Syndrome (HIV-AIDS) is a highly prevalent
disease within the Sub-Saharan region including South
Africa [1]. The broad aim of this study was to investigate
the role of salivary mucus and mucins (mucous glyco-
proteins) in HIV-AIDS. Sexual promiscuity and the sec-
ondary status of women in certain sectors of society
increase the risk for HIV transmission in these popula-
tions [1].
In a definitive study from our laboratory by Habte et
al [2], it was shown qualitatively that saliva from unin-
fected individuals together with its purified mucin com-
ponents MUC5B and MUC7 inhibited the HI-virus in
an in vitro assay. Habte et al [3] further showed that
MUC5B and MUC7 from saliva of infected individuals
did not inhibit the virus in an in vitro assay.
Both this study and the previous ones by Habte et al
[2,3] are based on the assumption of the presence of infec-
tious, viable HIV in the saliva [4]. Several researchers pro-
posed the presence of a key macromolecular component
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in saliva that could play a significant role in preventing
replication and subsequent infection of receptive cells by
HIV-1 [2,5-7]. A study by Archibald et al. [8] investigated
the in vitro inhibitory activities of saliva against the HIV-1
virus and found that whole saliva and specific glandular
salivas, except parotid secretions, were inhibitory. They
suggested that complexes of the virus with high molecular
weight submandibular mucins could play a role in viral in-
hibition [8]. A study by Wu et al. [9] and Malamud et al.
[10] identified salivary agglutinin as a possible macromol-
ecular component with a specific inhibitory role against
HIV-1 through interaction with viral envelope protein
gp120 and possible carbohydrate-mediated binding. The
postulate of Archibald et al. [8] and the findings of Habte
et al. [2,3] similarly suggest a specific interaction inhibi-
tory of HIV-1, in this case by the high molecular weight
mucin components of saliva, namely MUC5B and MUC7.
Mucins are high molecular weight glycoproteins with
complex O-linked oligosaccharide side-chains that are
found both in crude mucus gels and as transmembrane
proteins on the apical cell surfaces of glandular and
ductal epithelia of various organs [11]. There are a whole
host of transmembrane mucins with MUC1, MUC4 and
MUC16, being very well characterized and shown to be
aberrantly expressed in various malignancies including
cystic fibrosis, asthma and cancer [12]. It is also known
that oncogenic changes are associated with altered gly-
cosylation patterns in mucins, generating novel and ex-
ploitable epitopes in the fight against many cancers [11].
Genetic polymorphism of MUC7 alleles has been shown
to be associated with asthma in which a shorter MUC7
allele has protective properties [13] and a longer MUC2
allele may help protect atopic individuals [14]. MUC7
contains a central tandem repeat region and the most
common allele is comprised of 6 tandem repeats each of
69 nucleotides (base pairs) (23 amino acids) [15]. The
MUC5B gene is known to have a considerable poly-
morphism with respect to its 59-nucleotide tandem re-
peat region [16]. Desseyn et al. [16] observed 5 alleles in
a sample population of 86 unrelated individuals due to
3–8 GC-rich direct repeats of 59 base pairs. Therefore,
polymorphism in MUC genes is significant in its effect
on the number of possible glycosylation sites and is
likely to have an effect on the functional, physicochem-
ical properties of mucin, and is relevant in the suscepti-
bility and onset of certain diseases [15]. Indeed, the
polymorphisms within MUC5B and MUC7 genes may
play a role in the susceptibility to infection (by viruses
such as HIV). It has been proposed that variable charge
on the mucin molecule, due to altered glycosylation pat-
terns may affect its viral binding properties and the ag-
glutination of the viruses [2,17]. Nagashunmugam et al.
[18] observed inter-individual variation, which they
could quantify with respect to viral binding properties.
There has been an increasing interest in mucins in the
detection and treatment of carcinomas in general [19],
in particular as diagnostic and therapeutic agents [20].
The work by Habte et al. in our laboratory on the role
of mucus from HIV negative and HIV positive donors in
its inhibition of HIV in saliva [2,3,21], breast milk [22,23]
and cervical mucus [21], was an attempt to answer a novel
question of the role of mucus and mucins in the inhibition
of HIV-1. The limitation of that study [2] was that there
was no proper control group because ‘normal’ was based
on the declaration by the donor of the sample of having a
‘risk-free’ lifestyle. Also, the low yield of purified mucin
from individual samples necessitated the pooling of such
samples within both groups. This study which attempts to
verify the findings of Habte et al. [2] has two well defined
groups in which HIV negative samples were obtained
from individuals tested for HIV-AIDS whilst HIV positive
samples were obtained from patients clinically diagnosed
with the disease.
Results
Gel filtration and separation of MUC5B and MUC7 in
crude saliva
There was an inter-individual variation in the amounts
of material eluting under the void volume (V0) and
included volume (Vi) peaks and the shape and size of
the peaks, for both groups. The mucins in the void (V0)
and included volumes (Vi) of the column have previ-
ously been identified as MUC5B and MUC7 respectively
[24]. In 3 of the 20 HIV negative and 5 of the 20 HIV
positive samples respectively, the V0 peak was either ab-
sent or barely detectable whilst the Vi peak was seen for
all samples. The V0 peak, when present was always smal-
ler but slightly broader than the Vi peak which was
sometimes split as shown in SDS-PAGE [3,21], suggest-
ing the presence in some samples of two populations of
MUC7, varying slightly in size. MUC7 also eluted with
more protein positive material (proteins other than
mucins) than MUC5B (V0) (Figure 1).
Purification of mucin components by CsCl density-
gradient ultracentrifugation
Mucins which eluted from the V0 and Vi peaks of the
Sepharose gel filtration column were further purified by
density gradient ultra-centrifugation in CsCl for 48 h at
105 000 g, twice. Mucin-rich material fractionated at
the expected density of 1.42–1.45 g/ml, with most of the
associated protein having been removed during the
purification process. Apomucin (mucin protein back-
bone) is detected by the Lowry assay and seen as a smal-
ler peak under the larger mucin peak (Figure 2). The
mucin-rich fractions which eluted at densities close to
1.39–1.40 g/ml were pooled, dialysed and freeze dried
for further analysis.
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Amino acid analysis
The average serine, threonine and proline (S, T, and P)
content of the mucin for MUC5B was 27.47% and
28.55% for 3 HIV negative and positive samples respect-
ively. MUC7 from HIV negative samples had an S, T, P
content of 21.97% and that from HIV positive samples
was 23.61%.
Agarose gel-electrophoresis and Western blotting
Samples (n = 40) were run on 1% agarose gels and
transferred onto nitrocellulose membrane by vacuum
blotting. Mucin proteins were detected using rabbit anti-
MUC5B polyclonal and mouse anti-MUC7 monoclonal
primary antibodies respectively. Both the HIV negative
and positive samples for material eluted from the V0 of
the Sepharose 4B column (representation of samples
shown in Figure 3a, lanes 1 and 2) showed a trace of
MUC5B material near the top of the gel, with a smaller
sized and more highly charged species visible further
into the blot, that of the HIV positive sample being more
intense and charged (Figure 3a, lane 2) than that of the
control group (Figure 3a, lane 1). Migration of material
is affected by the charge and the length of the oligosac-
charide side-chains and the length of the polypeptide
Figure 1 The gel filtration profile of crude saliva from an HIV
negative donor. Crude saliva (20 ml in 6 M GuHCl, 10 mM EDTA,
1 mM PMSF pH 6.5) from an HIV negative donor was
chromatographed on a Sepharose CL-4B gel filtration column (bed
volume 200 ml). The column was eluted with 0.2 M NaCl: 0.02%
NaN3 at a flow rate of 60 ml/h at room temperature. An aliquot of
each fraction was assayed by the PAS and Lowry methods. V0
indicates the void volume and Vi indicates the included volume of
the column. Fractions 18–34 were pooled to recover MUC5B and
fractions 50–66 were pooled to recover MUC7. Fractions were
dialysed against three changes of distilled water overnight at 4°C,
and freeze-dried.
Figure 2 Profile of purification by caesium chloride density-
gradient ultracentrifugation of an HIV positive MUC7 sample.
Freeze dried material, in this example a sample of MUC7 (V0), was
dissolved in 4 M GuHCl containing 10 mM EDTA, 5 mM NEM, and
0.05% CHAPS pH 6.5, and adjusted to a density of 1.39 to 1.40 g/ml
with solid caesium chloride. Density-gradient centrifugation was
performed in a Beckman L45 ultra-centrifuge for 48 h at 40 000 rpm/
105 000 g, at 4°C. Fractions 3 and 4 were pooled, dialysed against 3
changes of distilled water overnight at 4°C and freeze-dried.
Figure 3 Western blotting analysis (representative) of HIV
negative and HIV positive salivary mucins MUC5B (a) and
MUC7 (b). a. lanes: 1, MUC5B (V0) HIV negative;2,MUC5B (V0) HIV
positive. b. lanes: 1, MUC7 (Vi) HIV negative;2, MUC7 (Vi) HIV positive.
Mucin proteins were detected using rabbit anti-MUC5B polyclonal
and mouse anti-MUC7 monoclonal primary antibodies respectively.
Dashed-arrows indicate loading position at the top of the gel
picture and further arrows indicate the migration distance of
samples.
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chain. Material eluted in the Vi of the Sepharose 4B col-
umn (Figure 3b, lanes 1 and 2) showed traces of MUC7
with similar intensities for the HIV negative (lane 1) and
HIV positive (lane 2) samples.
HIV-1 inhibition assay
On day 4 of the HIV-inhibition assay the HIV negative
crude saliva group showed positivity for p24, an indica-
tion of viral infection, in all 20 samples from each group.
Positivity for p24 in HIV positive crude saliva samples
was significant with a ratio of 16/20 p = 0.0114. Four of
twenty samples were negative for p24 in this group.On
day 7, positivity for p24 in the HIV negative crude saliva
group was 6/20. Fourteen samples showed negative
results for p24, that is no viral infection occurred, in this
group. Positivity for p24 in the HIV positive crude saliva
group was 5/20. Fifteen of twenty samples were negative
for p24 in this group. These results show a trend from
day 4 to day 7 for a decrease in positivity for p24 for
both HIV negative and HIV positive groups. Cross tabu-
lation data shows that the p24 variable did not differ by
HIV-status (Pearson Chi-square test shows no significant
difference between groups p = 0.723, p > 0.05). The p24
was negative for 14/20 (70.0%) HIV negative crude saliva
samples, and 15/20 (75.0%) HIV positive crude saliva
samples. On day 7, 14/20 (70.0%) HIV negative samples
were p24 negative, compared with HIV positive samples
where 15/20 (75.0%) were p24 negative.
To compare the p24 antigen assay results from days 4
and 7 for each group (HIV negative and HIV positive
crude saliva samples) McNemar statistical tests were
performed. On day 4, all HIV negative samples gave a
positive result for p24, hence no direct comparison be-
tween HIV negative and HIV positive groups was made
at this stage. Comparing day 4 and day 7 p24 results for
HIV positive samples a significant difference was found
(p = 0.001, p < 0.05), therefore the negativity for p24 on
day 7 was statistically significant.
Purified mucin samples of MUC5B and MUC7 for
both HIV negative and HIV positive groups at dilutions
of 10-1, 10-3, 10-5, 10-10, 10-20 and 10-40 were seen to in-
hibit HIV-1. The inhibition was observed for all but two
MUC5B and two MUC7 samples tested from each
group. Infection with HIV had occurred at one dilution
of 10-40 for MUC5B indicating the potential for a dose–
response relationship. Due to this small sample size a
statistical analysis of this group was not possible.
DNA analysis
Gel electrophoresis of MUC5B tandem repeat regions
(Figure 4) revealed numerous polymorphisms between
samples. There is some variation in the number of re-
peat polymorphisms in each of the samples from the
HIV negative group compared with those in the HIV
positive group. The sequence with 8 tandem repeats was
the most common genotype in both groups. Analysis of
heterozygosity of polymorphisms within MUC5B tan-
dem repeat gene fragments for both populations
revealed little difference between HIV negative and HIV
positive groups. The HIV negative group was 53% het-
erozygous whilst the HIV positive group was 60% het-
erozygous (Figure 4).
Gel electrophoresis of the tandem repeat regions of
the MUC7 gene (Figure 5) revealed that the repeat
structure for MUC7 was similar between all samples
with no influence of HIV status. All patients were homo-
zygous where the sequence contained 6 tandem repeats
(590 bp) in each gene copy, except for one sample from
the HIVnegative group that had a heterozygous genotype
of a 6 tandem repeat and a 5 tandem repeat (521 bp)
(Figure 5 arrow head).
Discussion
This is the first study quantifying the novel observations
made in our laboratory by Habte et al. [2] that crude sal-
iva, from uninfected individuals and its mucins MUC5B
and MUC7 inhibit HIV-1 in an in vitro assay. Crude sal-
iva from HIV positive patients was not studied by Habte
et al. [2,3,21]. The method we used was strictly accord-
ing to that of Habte et al. [21], who did not test for
mucin in the insoluble debris. This debris was shown to
have some mucin in saliva preparations, which was not
added to that in the supernatant in this study. Any HIV
Figure 4 Gel electrophoresis of the PCR product of MUC5B
tandem repeat regions showing variations in the number of
tandem repeats. Gel electrophoresis of the PCR product of MUC5B
tandem repeat regions showing variations in the number of tandem
repeats. A 2% agarose gel was used for MUC5B DNA samples. 20ul
of reaction mixture was loaded for each sample into each lane.
MWM marks those lanes loaded with a DNA molecular weight
marker. Ethidium bromide enabled DNA to be viewed under
ultraviolet light. Lanes 1–10 are HIV negative DNA samples and
11–20 HIV positive DNA samples (a representation of samples is
shown, lanes are numbered as such for clarity purposes).
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particles in the pellet would be rendered denatured by
the 6 M guanidinium hydrochloride in the extraction
media. Besides confirming Habte’s finding on normal
saliva and salivary mucin [2], we have gone on to show
that crude saliva and its purified mucins from HIV
infected individuals also inhibited HIV-1, in contrast to
the findings of Habte et al. [2,3,21], who reported that
HIV positive mucins did not inhibit the virus.
We consider this study to be quantitative in the sense
that it differs from previous studies of Habte et al. [2] in
that there were two major groups in this study, a diag-
nostically confirmed normal (n = 20) and infected group
(n = 20), and there was no pooling of sample in either
group. We do not claim to quantify mucins strictly by
assay because of the difficulties such a measurement
poses, due to the polydisperse or even heterogenous na-
ture of crude mucus secretions.
This quantitative study had several advantages over
the previous qualitative study of Habte et al. [2], in our
laboratory. Firstly, the HIV negative group of twenty
individuals were tested for HIV, unlike previously where
samples were taken on the basis of trust from patients
declaring a risk-free lifestyle with respect to sexual
habits and other risky behaviours such as the abuse of
drugs. Furthermore this study compared the inhibitory
potential of crude saliva in both groups together with
that of the mucins MUC5B and MUC7. Since Habte
et al. [2] did not test crude saliva from HIV positive
individuals and focussed only the salivary mucins
MUC5B and MUC7 purified from a pool of HIV positive
saliva [3], our findings raise new questions, encouraging
us to design future studies that will take into account
the treatment status of patients, the extent of the infec-
tion in relation to the CD4 counts and a wider genetic
study of mucins in a population in this region. It is inter-
esting that a few samples in both groups did not inhibit
the virus. This may be due to inter-individual variation
in mucin concentration of the crude saliva samples. The
establishment of a dose–response curve, which we are
busy with, will help answer such questions. It had not
been done because of limitations in terms of time con-
straints, sample yield (we used individual samples) and
location (these experiments were carried out in the Div-
ision of Virology at the University of Stellenbosch in
which there was this established assay made available to
us and in which laboratory space was shared due to
restricted conditions).
Crude saliva is conveniently separated into its mucin
components with MUC5B eluting in the V0 and MUC7
in the Vi of a Sepharose CL-4B gel filtration column.
However, there was inter-individual variation within nor-
mal and infected groups, especially for MUC5B which in
some instances seemed hardly detectable, whilst in other
cases eluted as a small but broad peak from the column.
When comparing the biochemical properties of mucins
from normal saliva and that from HIV-infected patients,
both groups had more MUC7 material than MUC5B.
The reason for this is unknown but it is not an exact
measure in the strict sense of a mucin assay (with refer-
ence to a standard curve), but rather a more general as-
sessment based on the size of peaks eluting from the
column, an indicator of amounts of material on a broad
comparative basis, like has been previously reported in
other studies on mucins in the stomach [25,26]. All sam-
ples showed a larger MUC7 peak, the shape of which
differed from sample to sample and was associated with
considerable amounts of protein compared to the
MUC5B of the void volume. In some instances this peak
was split, suggesting a variation in the MUC7 popula-
tion, in keeping with Habte’s findings of two bands of
purified MUC7 on Western blotting after 4-20% gradient
gel electrophoresis [3].
Crude saliva and purified mucins from both groups
inhibited the virus in an in vitro assay. Mucins were
purified by density gradient ultra-centrifugation in CsCl,
a long-established procedure shown to free mucins in
complex secretions from contaminating protein [27-29].
Salivary mucins MUC5B and MUC7, purified from the
saliva of HIV positive patients, were previously shown
by 4-20% gradient SDS-PAGE to be pure and Western
Figure 5 Gel electrophoresis of the PCR product of MUC7
tandem repeat regions showing variations in the number of
tandem repeats. A 1% agarose gel was used for MUC7 DNA
samples. 20ul of reaction mixture was loaded for each sample into
each lane. MWM marks those lanes loaded with a DNA molecular
weight marker. Ethidium bromide enabled DNA to be viewed under
ultraviolet light. Lanes 1–10 are HIV negative DNA samples and
11–20 HIV positive DNA samples (a representation of samples is
shown, lanes are numbered as such for clarity purposes). A single
band (590 bp) represents the tandem repeat fragment with six
repeats indicating a donor who is homozygous for MUC7. The
double band, marked with an arrow, is of the fragment with six
repeats and the smaller sized band (521 bp) is the fragment with
five repeats. This indicates a heterozygous genotype for the donor
for MUC7.
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Blotting confirmed the identity of these mucins [3]. The
amino acid analysis is characteristic of purified O-
glycosylated mucin in its serine, threonine and proline
(S, T and P) content [29], which was slightly higher in
the HIV positive group. The significance of this is not
known and since only 3 samples from each group were
analysed, a statistical analysis was not done.
It may be worthwhile to determine further whether the
roles of MUC5B and MUC7 vary in the inhibition of HIV-
1. A study by Thomsson et al [30] highlights the differ-
ences in glycosylation between MG1 (MUC5B) and MG2
(MUC7). They identified that MG1-derived oligosacchar-
ides (sugar side chains attached to the protein molecule)
were significantly longer than those of MG2. This is in
keeping with the findings in this study that MUC5B was a
larger molecule than MUC7 and eluted in the void volume
(V0) of the Sepharose Cl-4B column, although the length
and size of the polypeptide may not necessarily relate to
the length of oligosaccharides. A greater extent of glycosy-
lation may be indicative of a more relevant role in the in-
hibition of HIV-1 transmission. Interestingly it is a feature
of cancer-related mucins to be under-glycosylated and to
have an altered glycosylation pattern when compared with
normal mucins [11,31]. A more glycosylated molecule
with longer oligosaccharides could more effectively aggre-
gate virus particles. Some of these questions would form
the basis for future research.
Western blotting detection of purified salivary mucin
samples revealed a large amount of MUC5B in HIV
negative samples compared with trace amounts of
MUC5B in HIV positive samples. MUC7 was detected
in both HIV negative and HIV positive samples
(Figure 3b). Here however the charge of the oligosac-
charides on the apomucin can influence migration of the
mucin through an agarose gel.
Purified salivary mucins MUC5B and MUC7 with dilu-
tions of 10-1, 10-3, 10-5, 10-10, 10-20 and 10-40, provided a
wider range than that used by Habte et al. [2], and showed
the potency of the mucin in the inhibition of the virus at
very low concentrations and high dilutions. The finding of
Habte et al. [3] that MUC5B and MUC7 from the saliva
of patients who are HIV positive did not inhibit mucins is
an essential difference to our finding in this study. If any
variation existed in the inhibitory potential of mucins
from sample-to-sample, this would be masked by the
pooling of these individual samples. There is a large
amount of other protein contaminants in crude saliva and
their inhibitory potential needs to be investigated. These
include cystatins (inhibitors of cysteine proteases), anti-
bodies (sIgA) and, in addition to mucins, other high mo-
lecular weight glycoproteins such as salivary agglutinin
(SAG) [9,32]. SAG has been shown to have a specific in-
hibitory effect through interaction with viral capsid glyco-
protein gp120 [9]. A larger study is being planned to
investigate these questions, especially a comparison of the
inhibitory properties of mucins versus other components
such as gp340 in the inhibition of the virus.
DNA analysis of tandem repeat regions in the genes of
MUC5B and MUC7 from HIV negative and HIV positive
donors revealed no association of HIV-infection status and
gene polymorphisms. Polymorphisms are distributed be-
tween both groups. There is no apparent link between het-
erozygosity or homozygosity in either the MUC5B or
MUC7 tandem repeat alleles and HIV-infection. This sug-
gests that there is no genetic predisposition for the suscepti-
bility to HIV-infection. An investigation of the variation in
the genetic and protein structure of mucins MUC5B and
MUC7 and their association with infection with HIV is a
study that could be engendered by these findings.
One area of research aimed at the reduction of infec-
tion in this region is the development of microbicides
which can enhance the body’s first line of defence
against the virus. A formulation or preparation, in which
mucins could form a part of a barrier substance, may be
an idea worth exploring. Secreted mucins such as
MUC5B form gels in the respiratory and other internal
tracts of the body which protect epithelia lining the mu-
cosae of these tracts from harmful factors in a hostile
milieu. One such example is the crude mucus gel lining
the surface of the gastric mucosa, a 200 μM thick barrier
which forms an unstirred layer on the gastric mucosal
surface and protests it from hydrochloric acid (down to
pH 1), pepsin activity and the shear forces associated
with digestion [33]. Our findings suggest that the virus
could be trapped by mucins in the saliva. We suggest
that the biochemical structure of these mucins, together
with the physical properties of the crude mucus, could
make a mucus-based formulation (a substance or prep-
aration that contains mucins or even crude mucus as a
component of the preparation) an effective barrier, pro-
tecting the vaginal mucosa against the shear associated
with sexual intercourse and remaining intact long
enough to resist the infection of the mucosal cells by the
HI virus. Studies amenable to identifying a peptide or
short polypeptide with activity that could be developed
into a microbicide are also in progress.
Conclusions
Crude salivary mucus and the purified salivary mucins
MUC5B and MUC7 play a role in the inhibition of HIV-
1 in the oral cavity. This inhibition is not limited to sal-
iva and its purified mucins from HIV negative donors,
but includes that from HIV positive patients.
Methods
Ethics
The University of Cape Town Research and Ethics Com-
mittee approved this study (ethics approval number REC
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REF: 283/2004). Prior to collection of sample, each pa-
tient or participant in the study was provided with a
consent form and an information sheet explaining the
nature and scope of the project. Informed consent was
then obtained by signature of the patient/participant, be-
fore the sample was collected.
Saliva collection, mucin preparation and analysis
Saliva was collected from tested HIV negative indivi-
duals (n = 20) (Voluntary Counseling and Testing Drive
at the University of Cape Town) and HIV positive
patients (n = 20) (HIV-positive Clinic, Groote Schuur
Hospital, Cape Town). The preparation and purification
of salivary mucins was according to the method
described by Habte et al. [2]. Briefly, each sample of
crude saliva (supernatant fluid after gentle stirring and
centrifugation to remove large debris) was separated by
Sepharose CL-4B and subsequently purified by caesium
chloride isopycnic density gradient ultra-centrifugation
[34]. Mucins were further analysed by agarose gel elec-
trophoresis and Western blotting [35]. Amino acid ana-
lysis was performed for 3 samples from each group [35].
Glycoprotein was estimated by the PAS procedure of
Mantle and Allen [36] and protein according to the
method of Lowry et al. [37].
HIV-1 inhibition assay
The inhibition assay was a variation of the one described
by Habte et al. [2,21]. It allowed for the detection of the
anti-HIV-1 activities of crude saliva and purified salivary
mucins MUC5B and MUC7 from both HIV negative and
HIV positive individuals in in vitro cell culture experi-
ments as described by Nagashunmugam et al. [18]. Mucin
at a concentration of 1 mg/ml was dissolved in 0.25% PBS
(dilution in distilled water) and a dose–response curve
established using dilutions of 10-1, 10-3, 10-5, 10-10, 10-20
and 10-40 of the original concentration. HIV-1 plus media
(RPMI 1640 with 10% fetal calf serum, penicillin and
streptomycin, obtained from Gibco, Massachusetts, USA)
was used as a positive control. Negative controls used
were culture media alone and media incubated with
PBMCs (Peripheral blood mononuclear cells).
The virus used in the assay was TV167, a subtype C
HIV-1 isolate that is the most common subtype in
Southern Africa. This specific isolate is a dualtropic
strain that expresses CCR5 and CXCR4 co-receptors
equally, mimicking the virus during all stages of its pro-
liferation during an infection and therefore reducing
variables for the experiment. Another subtype C HIV-1
isolate (TV671) was included in the experiments as an
additional positive control.
One hundred microlitres of pure mucin sample was
mixed with 400ul HIV-1 supernatant fluid (p24 antigen-
positive supernatant after virus isolation by PBMC co-
culture) and incubated for 60 min at 37°C (5% humidity,
95% [CO2]). The samples were then filtered using 1.0 ml
0.25% PBS through a 0.45um hydrophilic cellulose acet-
ate membrane (PRO-X Filter Unit, Lida Manufacturing
Corp.). After incubation and filtration, the filtrate con-
taining free virus was discarded, and the unfiltered
(retained) samples (containing mucin components and
‘trapped’ virus particles) were recovered using 0.5 ml
0.25% PBS.
PBMCs were isolated using the Ficoll density-gradient
method after being pooled from different HIV negative
donors and stimulated with PHA (4 days before the
assay) and IL −2 (two days before the assay). Four hun-
dred microlitres of the unfiltered sample was then incu-
bated with 100ul of PBMCs at 37°C (5% humidity, 95%
[CO2]), the plate centrifuged on day 4, at 1000 rpm for
10 min and the supernatant fluid harvested and stored
at −80°C for the p24 ELISA assay (Vironostika HIV-1
Antigen kit was obtained from Biomerieux, Nether-
lands). Media was replaced with cells and cultured and
viral infection of the cells was measured using an assay
for the quantitative estimation of p24 antigen. The quali-
tative cut off value was calculated by the average optical
density values of the 3 p24-negative kit controls plus a
constant of 0.07. Samples with absorbance values less
than the cut-off value are considered nonreactive by the
criteria of Vironostika HIV-1 antigen kit (Biomerieux,
Netherlands) and may be considered negative for HIV-1
antigen.
DNA extraction and analysis
DNA analysis was performed in order to establish
whether there is a difference between HIV negative and
HIV positive samples in the tandem repeat region of the
mucin genes MUC5B and MUC7. The DNA was
extracted and purified from buccal swabs taken from
HIV negative (n = 20) and HIV positive (n = 20) saliva
donors. The swabs were allowed to air dry and centrifu-
gation steps were carried out at RT prior to DNA ex-
traction procedures. The protocol for DNA purification
from buccal swabs (Spin protocol) for isolation of total
genomic, mitochondrial and viral DNA and RNA was
followed as described in the QIAamp DNA Mini and
Blood Mini Handbook and used a QIAamp DNA Mini
kit (obtained from Southern Cross Biotechnology). PCR
(polymerase chain reaction), of the tandem repeat
regions of each of the MUC genes allowed for poly-
morphisms in these regions to be identified and any cor-
relation with the HIV infection status of the donor to be
noted.
Gene amplification using PCR
PCR was used to determine the presence or absence of
polymorphisms in the tandem repeat regions of MUC5B
Peacocke et al. Virology Journal 2012, 9:177 Page 7 of 9
http://www.virologyj.com/content/9/1/177
and MUC7. Primers flanking these tandem repeat
regions were used to amplify samples from both HIV
negative and HIV positive individuals. PCR primers
(Whitehead Scientific):MUC7 – Primer 1 (forward): 5’-
GTA GCT ACA TTA GCA CCA GTG-3’; primer 2 (re-
verse): 5’-TTC AGA AGT GTC AGG TGC AAG-3’.
MUC5B – Primer 1 (forward): 5’-AGT GTG CAG TGA
CTG GCG AG-3’;primer 2 (reverse): 5’-CTA GAG TTG
CAG GTG GCA GG-3’.
Each PCR consisted of a 50ul reaction containing of
1X GoTaq buffer (Promega, Wisconsin), 3 mM MgCl,
200uM of each dNTPs, 1uM of each primer, approxi-
mately 0.5ug of DNA and 2.5 units of GoTaq DNA poly-
merase (Promega, Madison, Wisconsin). Amplification
conditions for MUC5B were as follows: initial denatur-
ation at 95°C for 3 min followed by 30 cycles of denatur-
ation at 95°C for 30secs, primer annealing at 60°C for
30secs and extension at 72°C for 45secs. A final exten-
sion step was done at 72°C for 7 min. Amplification con-
ditions for MUC7 were as follows: initial denaturation at
94°C for 2 min and then 30 cycles of denaturation at
94°C for 30secs, primer annealing at 60°C for 30secs and
extension at 72°C for 30secs. A final extension step was
done at 72°C for 6 min.
Agarose gel electrophoresis for DNA polymorphism
analysis
MUC5B and MUC7 products were analysed on a 2%
and 1% agarose gel respectively. Twenty microlitres of
reaction mixture was loaded for each sample and a 1 kb
DNA ladder (Promega, Wisconsin) was used to deter-
mine the sizes of bands. Gels were run in 1X TAE (Tris
acetic acid with EDTA) buffer at 60 V for 2 h. Ethidium
bromide (EtBr) enabled the DNA to be viewed using
ultraviolet light.
Statistical analysis of data
Under the hypothesis that 70% of patient samples in the
two compared groups (HIV negative and HIV positive
samples) would be p24-positive in the HIV-1 inhibition
assay, and based on a power of 0.80 and a level of sig-
nificance of 0.05, an estimated sample size of 18 patients
was calculated. Thus, a sample size of 20 subjects was
selected for this study.
Categorical data was compared using Pearson Chi-
square tests (or the Fisher’s exact test) whenever appro-
priate. The McNemar test was used for comparing the
p24 assay results at days 4 and 7 of the HIV-1 inhibition
assay. All tests were 2-sided and a p-value <0.05 was
considered as significant.
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